Cellino Biotech Strengthens Leadership Team
Cellino Biotech, Inc., a pioneering biotechnology firm dedicated to advancing autonomous closed biomanufacturing technologies for personalized regenerative medicines, has announced a significant addition to its leadership team with the appointment of Chris Gemmiti, Ph.D., as the Senior Vice President of Therapeutics Development. Dr. Gemmiti brings a wealth of experience—over 25 years—spanning both academic and industry roles in cell therapy and regenerative medicine.
Expertise in Regenerative Medicine
Dr. Gemmiti's extensive background makes him an excellent fit for this new role. He is recognized for his leadership in developing innovative therapeutics, showcasing his exceptional capabilities in navigating the complexities of the biotech landscape. Nabiha Saklayen, Ph.D., CEO & Co-Founder of Cellino, expressed enthusiasm about Dr. Gemmiti's arrival, stating that his scientific and leadership prowess will be a major asset as Cellino aims to advance its therapeutic pipeline and forge strategic partnerships.
Pivotal Achievements Prior to Cellino
Before joining Cellino, Dr. Gemmiti served as the Vice President of Technical Operations at CRISPR Therapeutics, where he had pivotal responsibilities in the development of groundbreaking therapies. Notably, he led the Chemistry, Manufacturing, and Controls (CMC) for CASGEVY, the groundbreaking CRISPR gene-edited treatment recognized as the first approved therapy for sickle cell anemia and ?-thalassemia. His leadership in establishing technical operations and CMC has positioned him as a key player in the biotech field.
Hands-On Experience with Clinical Trials
Dr. Gemmiti's career includes serving as the Senior Vice President of Operations at Sentien. There, he oversaw a range of operational activities for the clinical-stage company focused on mesenchymal stem cell therapies, significantly impacting the company’s strategic direction. He played a critical role in launching Sentien’s Investigational New Drug application for COVID-19 patients experiencing multiple organ failure, showcasing his ability to bridge research and practical applications in critical health situations.
A Vision for the Future of Biomanufacturing
In his own words, Dr. Gemmiti expressed excitement about joining Cellino during its pivotal growth phase. He is particularly drawn to Cellino’s innovative approach to high-precision, autonomous biomanufacturing technology that promises to reshape how personalized regenerative medicines are delivered at scale. His commitment aligns with Cellino's mission to tackle the pressing challenges in transformative medical treatments, aiming to advance the development of revolutionary therapies that cater to patient-specific needs.
Academic Credentials and Advisory Roles
Dr. Gemmiti’s academic background is equally impressive; he earned his Ph.D. in Biomedical Engineering from Georgia Tech, complemented by recognition as an NSF Fellow in Entrepreneurship. He also holds a Bachelor’s degree in Biomedical Engineering from Johns Hopkins University. His involvement in advisory boards at prestigious institutions like Georgia Tech, Duke University, and TERMIS highlights his ongoing contributions to advancing regenerative medicine research and practices.
About Cellino Biotech
Cellino is dedicated to revolutionizing the field of regenerative medicine through its ultra-scalable, high-precision biomanufacturing technology. This innovative approach aims to ensure that personalized treatment options are accessible and efficient for patients. To learn more about Cellino and their work, visit their official website for the latest updates and follow them on professional networks to stay connected with their latest endeavors.
Frequently Asked Questions
Who is Chris Gemmiti?
Chris Gemmiti, Ph.D., is the newly appointed Senior Vice President of Therapeutics Development at Cellino Biotech, Inc., with over 25 years of experience in the field.
What are Dr. Gemmiti's previous roles?
Before Cellino, Dr. Gemmiti was Vice President of Technical Operations at CRISPR Therapeutics and Senior Vice President at Sentien.
What is Cellino's mission?
Cellino aims to develop autonomous high-precision biomanufacturing technologies to enhance personalized regenerative medicine delivery.
What is the significance of Dr. Gemmiti's appointment?
His extensive expertise is expected to accelerate the development of novel therapeutics and strengthen Cellino's strategic partnerships.
How does Cellino's technology benefit patients?
Cellino's approach aims to make personalized regenerative treatments scalable and accessible to patients, addressing critical health challenges.
